Users Online: 181
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2012  |  Volume : 1  |  Issue : 1  |  Page : 30-35

Metastatic renal cell carcinoma: Current scenario and future trends


Department of Medical Oncology and Hematology, Patel Cancer and Superspeciality Hospital, Jalandhar City, Punjab, India

Correspondence Address:
Anubha Bharthuar
Department of Medical Oncology and Hematology, Patel Cancer and Superspeciality Hospital, Jalandhar City, Punjab
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2278-330X.96505

Rights and Permissions

An improved understanding of the biology of renal cell carcinoma (RCC) has led to the development of a number of targeted agents, which has resulted in a paradigm shift in the management of metastatic RCC. We review the current therapeutic strategies for metastatic RCC and present a synopsis of the novel agents in use today with a discussion of the phase III trials that demonstrated their clinical benefit. The management of RCC continues to evolve. The introduction of VEGF and mTOR inhibitors has markedly expanded our drug armamentarium and improved the outcome of a disease that has always been challenging to treat. Knowledge from upcoming trials will help us utilize these drugs for maximum clinical efficacy with optimal dosing and sequencing, either individually or in combination therapy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2308    
    Printed130    
    Emailed1    
    PDF Downloaded382    
    Comments [Add]    

Recommend this journal